SCHEMBL6720846

SCHEMBL6720846

CCCCCCCCCCCCCCCCCC1=NN(c2ccc(Oc3ccccc3)c(S(=O)(=O)O)c2)C(=O)C1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.48
L3MBTL1 Q9Y468 3/20 0.48
ALDH1A1 P00352 2/20 0.48
KDM4E B2RXH2 1/20 0.48
MAPT P10636 1/20 0.48
ALOX15 P16050 1/20 0.48
DUSP3 P51452 1/20 0.48
PTPN5 P54829 1/20 0.48
PTPN11 Q06124 1/20 0.48
HSD17B10 Q99714 1/20 0.48
CTDSP1 Q9GZU7 1/20 0.48
RXFP1 Q9HBX9 2/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
APEX1 P27695 1/20 0.46
SHMT2 P34897 1/20 0.43
GAA P10253 2/20 0.39
MAOB P27338 6/20 0.37
MAOA P21397 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14429858 0.91 TBXA2R (0.41) POLBL3MBTL1ALDH1A1KDM4EMAPT
SCHEMBL14429924 0.83 MAPT (0.48) POLBL3MBTL1ALDH1A1KDM4EMAPT
SCHEMBL14429923 0.83 MAPT (0.48) POLBL3MBTL1ALDH1A1KDM4EMAPT
SCHEMBL6731840 0.83 MAPT (0.48) POLBL3MBTL1ALDH1A1KDM4EMAPT
SCHEMBL14429913 0.83 MAPT (0.48) POLBL3MBTL1ALDH1A1KDM4EMAPT
SCHEMBL6726311 0.83 MAPT (0.48) POLBL3MBTL1ALDH1A1KDM4EMAPT
SCHEMBL14429839 0.80 POLB (0.47) POLBL3MBTL1ALDH1A1KDM4EMAPT
SCHEMBL14429925 0.79 SOAT2 (0.46) POLBL3MBTL1ALDH1A1KDM4EMAPT
SCHEMBL7831352 0.79 POLB (0.56) POLBL3MBTL1ALDH1A1KDM4EMAPT
SCHEMBL14429863 0.79 POLB (0.47) POLBL3MBTL1ALDH1A1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070185176-A1 Heparanase inhibitors and uses thereof INSIGHT BIOHARMACEUTICALS LTD. (IL) 2007-08-09 US disclosed
US-20070185176-A1 Heparanase inhibitors and uses thereof INSIGHT BIOHARMACEUTICALS LTD. (IL) 2007-08-09 US disclosed
US-6677473-B1 TREATMENT, PREVENTION OR AMELIORATION OF ONE OR MORE SYMPTOMS OF THROMBOTIC DISORDERS, UNSTABLE ANGINA OR CANCER CORVAS INTERNATIONAL INC 2004-01-13 US disclosed
WO-2001036351-A2 PLASMINOGEN ACTIVATOR INHIBITOR ANTAGONISTS RELATED APPLICATIONS CORVAS INTERNATIONAL, INC. (US) 2001-05-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185176-A1 Heparanase inhibitors and uses thereof HPSE, ENGASE, HEXA POLB 3716/4885L3MBTL1 3342/4885ALDH1A1 2507/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.